Abstract
The present study was designed to attempt to clarify the mechanism by which the specific beta-2 adrenergic agonist albuterol causes an enhancement of erythropoietin (Ep) production in the isolated perfused dog kidney. We have postulated previously that prostaglandins (PG) release is an early event in initiating a cascade which leads to enhanced kidney production of Ep. In the present study, the posthypoxic dog kidney was perfused for 5 hr with blood containing 500 microgram/l of albuterol. A significant (P<.001) increase in prostaglandin E (PGE) concentration was seen as early as 1 hr and continued to rise over the 5-hr perfusion period. This microgram increase in PGE was correlated with a significant (P<.05) increase in Ep titers in the perfusates after 3 and 5 hr perfusion. The addition of the PG cyclooxygenase inhibitor meclofenamate (1000 micrograms/l) to the perfusate together with albuterol completely abolished the albuterol-induced increase in PGE and Ep generation in the isolated perfused kidney. No significant increase in PGE or Ep titers in the perfusates occurred during the 5-hr perfusion period in the saline and albuterol plus meclofenamate perfused groups. These data suggest that beta-2 adrenergic activation of Ep production is correlated with an increase in PGE production by the kidney which may be related to the mechanism by which beta-2 agonists enhance kidney production of Ep.
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|